Cellectar Biosciences (CLRB)
NASDAQ:CLRB
Want to see CLRB full AI Analyst Report?
CLRB Stock Chart & Stats
$3.29
-$0.03(-9.33%)
At close: 4:00 PM EST
$3.29
-$0.03(-9.33%)
Day’s Range― - ―
52-Week Range$2.43 - $20.61
Previous CloseN/A
Volume1.30M
Average Volume (3M)105.19K
Market Cap
$21.90M
Enterprise Value$3.20M
Total Cash (Recent Filing)$8.35M
Total Debt (Recent Filing)$1.53M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Aug 19, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.38
Shares Outstanding7,991,812
10 Day Avg. Volume157,484
30 Day Avg. Volume105,193
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.78
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market Cap0.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit29.13
Enterprise Value/Ebitda-0.14
Forecast
1Y Price Target
$10.33Price Target Upside214.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.13
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
PLE Tumor-targeting PlatformA proprietary PLE tumor-targeting platform provides a structural competitive advantage by enabling selective delivery of radioisotopes and companion imaging. That platform-level differentiation supports multiple program applications, partnerability and potential barriers to entry that remain relevant through clinical development and commercialization.
Robust Phase IIb CLOVER WaM DataStrong, durable Phase IIb efficacy (high ORR, long DOR and meaningful PFS) materially de-risks the lead asset from a clinical perspective. This supports the Breakthrough designation and a credible accelerated-approval/Phase III pathway, improving the odds of regulatory success and future commercial traction over the medium term.
Material Financing To Support Late-stage WorkAn oversubscribed financing that supplies upfront capital and milestone funding materially extends runway to initiate a Phase III and prepare regulatory filings. This financing reduces immediate liquidity pressure and enables execution of planned pivotal work, increasing the likelihood the company can reach value-inflection clinical and regulatory milestones.
Bears Say
No Commercial RevenueAbsence of product revenue leaves the company dependent on financing and milestones to fund operations. Without an established commercial base, long-term sustainability hinges on successful trials, regulatory approval and partner/commercial execution, which lengthens the time to self-sustaining cash generation and raises execution risk.
Sustained Cash BurnSignificant negative operating and free cash flow indicate ongoing consumption of capital. Even with improvement vs prior year, persistent burn requires recurring external funding and makes timelines sensitive to financing availability, increasing dilution risk and constraining strategic optionality over the next several quarters.
Eroded Equity And Limited Balance-sheet CushionMaterial equity erosion and a history of negative equity reduce financial resilience and bargaining power. A thinner capital cushion limits the company's ability to absorb setbacks, increases reliance on dilutive financings for development, and constrains flexibility in partnering or opportunistic investments during pivotal development stages.
Cellectar Biosciences News
CLRB FAQ
What was Cellectar Biosciences’s price range in the past 12 months?
Cellectar Biosciences lowest stock price was $2.43 and its highest was $20.61 in the past 12 months.
What is Cellectar Biosciences’s market cap?
Cellectar Biosciences’s market cap is $21.90M.
When is Cellectar Biosciences’s upcoming earnings report date?
Cellectar Biosciences’s upcoming earnings report date is Aug 19, 2026 which is in 76 days.
How were Cellectar Biosciences’s earnings last quarter?
Cellectar Biosciences released its earnings results on May 14, 2026. The company reported -$1.33 earnings per share for the quarter, beating the consensus estimate of -$1.885 by $0.555.
Is Cellectar Biosciences overvalued?
According to Wall Street analysts Cellectar Biosciences’s price is currently Undervalued.
Does Cellectar Biosciences pay dividends?
Cellectar Biosciences does not currently pay dividends.
What is Cellectar Biosciences’s EPS estimate?
Cellectar Biosciences’s EPS estimate is -0.48.
How many shares outstanding does Cellectar Biosciences have?
Cellectar Biosciences has 7,991,812 shares outstanding.
What happened to Cellectar Biosciences’s price movement after its last earnings report?
Cellectar Biosciences reported an EPS of -$1.33 in its last earnings report, beating expectations of -$1.885. Following the earnings report the stock price went up 8.844%.
Which hedge fund is a major shareholder of Cellectar Biosciences?
Currently, no hedge funds are holding shares in CLRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectar Biosciences
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
CLRB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized major clinical progress for iopofosine (robust Phase IIb 12‑month data with high ORR, durable responses, and regulatory strategy toward accelerated approval) and an oversubscribed financing structure intended to fund late‑stage development. Operational progress on CLR125 and cost discipline were also highlighted. Key risks include a low pre‑financing cash balance, reliance on milestone‑contingent funding with market‑performance conditions, continued net losses, and tight timelines for Phase III initiation and regulatory milestones. On balance, the positive clinical data and financing momentum significantly outweigh the contingent funding and timing risks.View all CLRB earnings summariesCLRB Stock 12 Month Forecast
Average Price Target
$10.33
▲(214.08% Upside)
Technical Analysis
Ownership Overview
0.59% Insiders
1.45% Mutual Funds
1.56% Other Institutional Investors
95.38% Public Companies and
Individual Investors